Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AlloRx for Idiopathic Pulmonary Fibrosis
NCT05016817Phase 1Terminated
- Sponsor
- The Foundation for Orthopaedics and Regenerative Medicine
- Start
- Jul 2022
- Primary completion
- Nov 2025
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of AlloRx in idiopathic pulmonary fibrosis (IPF), sponsored by The Foundation for Orthopaedics and Regenerative Medicine. Primary endpoint: Adverse Events at 48 months. Started Jul 2022; status: terminated.
02
Drugs
AlloRx
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT05016817.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05016817.